Elicera Therapeutics (ELIC) investor relations material

Phase I results

• All 12 patients in the CARMA dose-escalation phase were treated and evaluated for preliminary efficacy at least at one-month follow-up; no dose-limiting toxicities were observed across three cohorts, and ELC-301 was well tolerated.

• CMR rate was 67% (8/12), ORR 92% (11/12) and disease control rate 100% (12/12).

• Six of the eight patients who achieved CMR remain in CMR; two later progressed after responding. One patient had confirmed CMR for at least 18 months and another for at least 12 months.

• All three patients who had relapsed after prior CAR T-cell therapy achieved disease control; two had an objective response, including one CMR.

• Patients generally had extensive prior treatment, including multiple chemotherapy lines, stem cell transplantation and, in three cases, prior CAR T-cell therapy.

Study design and next steps

• CARMA evaluates ELC-301 in relapsed or refractory B-cell lymphoma after at least two prior standard-treatment lines, for patients with no remaining curative treatment options.

• Phase I enrolled 12 patients across three dose cohorts to establish dose and safety; Phase IIa will evaluate six additional patients at the maximum tolerated dose.

• The Swedish Medical Products Agency approved a substantial trial modification permitting Phase IIa; recruitment is expected to begin in Q4 2026.

ELC-301 and iTANK

• ELC-301 is a fourth-generation CD20-targeting CAR T-cell therapy armed with the iTANK platform to activate a broader parallel immune response against cancer.